Literature DB >> 30267125

[Differentiated laboratory diagnostics of rheumatic diseases].

C Specker1.   

Abstract

Laboratory diagnostics of rheumatic diseases include examinations to confirm the diagnosis, estimate prognosis, assess disease activity as well as recognition and avoidance of complications. Although detection and clinical classification of serological signs of inflammation are the first and often decisive steps in the diagnosis of inflammatory rheumatic diseases, a lack of humoral signs of inflammation does not rule out an inflammatory rheumatic disease. Rheumatological and immunological laboratory diagnostics should always be assessed in the context of the clinical issue and other clinical and technical findings.

Entities:  

Keywords:  Anti-citrullinated protein antibodies; Antibodies, antineutrophil cytoplasmic; Antibodies, antinuclear; C-reactive protein; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 30267125     DOI: 10.1007/s00132-018-3651-3

Source DB:  PubMed          Journal:  Orthopade        ISSN: 0085-4530            Impact factor:   1.087


  18 in total

1.  Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases.

Authors:  Henrique A Mariz; Emília I Sato; Silvia H Barbosa; Silvia H Rodrigues; Alessandra Dellavance; Luis E C Andrade
Journal:  Arthritis Rheum       Date:  2011-01

Review 2.  The diagnostic accuracy of procalcitonin for bacteraemia: a systematic review and meta-analysis.

Authors:  S H Hoeboer; P J van der Geest; D Nieboer; A B J Groeneveld
Journal:  Clin Microbiol Infect       Date:  2015-01-14       Impact factor: 8.067

3.  International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies.

Authors:  Nancy Agmon-Levin; Jan Damoiseaux; Cees Kallenberg; Ulrich Sack; Torsten Witte; Manfred Herold; Xavier Bossuyt; Lucille Musset; Ricard Cervera; Aresio Plaza-Lopez; Carlos Dias; Maria José Sousa; Antonella Radice; Catharina Eriksson; Olof Hultgren; Markku Viander; Munther Khamashta; Stephan Regenass; Luis Eduardo Coelho Andrade; Allan Wiik; Angela Tincani; Johan Rönnelid; Donald B Bloch; Marvin J Fritzler; Edward K L Chan; I Garcia-De La Torre; Konstantin N Konstantinov; Robert Lahita; Merlin Wilson; Olli Vainio; Nicole Fabien; Renato Alberto Sinico; Pierluigi Meroni; Yehuda Shoenfeld
Journal:  Ann Rheum Dis       Date:  2013-10-14       Impact factor: 19.103

Review 4.  The Clinical Relevance of Anti-DFS70 Autoantibodies.

Authors:  Karsten Conrad; Nadja Röber; Luis E C Andrade; Michael Mahler
Journal:  Clin Rev Allergy Immunol       Date:  2017-04       Impact factor: 8.667

5.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

6.  How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis.

Authors:  Henk Visser; Saskia le Cessie; Koen Vos; Ferdinand C Breedveld; Johanna M W Hazes
Journal:  Arthritis Rheum       Date:  2002-02

Review 7.  C-reactive protein in rheumatology: biology and genetics.

Authors:  Benjamin Rhodes; Barbara G Fürnrohr; Timothy J Vyse
Journal:  Nat Rev Rheumatol       Date:  2011-04-05       Impact factor: 20.543

Review 8.  [Novel immunodiagnostics for inflammatory arthritis].

Authors:  M Wahle; E Kling
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

9.  Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States.

Authors:  Tuulikki Sokka; Theodore Pincus
Journal:  J Rheumatol       Date:  2009-05-01       Impact factor: 4.666

Review 10.  [Antinuclear antibodies without connective tissue disease : Antibodies against LEDGF/DSF70].

Authors:  R Mierau
Journal:  Z Rheumatol       Date:  2016-05       Impact factor: 1.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.